Skip to main content
IGC Pharma, Inc. logo

IGC Pharma, Inc. — Investor Relations & Filings

Ticker · IGC ISIN · US45408X3089 LEI · 529900TIWO8H06FQC983 US Professional, scientific and technical activities
Open in API
Filings indexed 764 across all filing types
Latest filing 2026-06-08 Capital/Financing Update
Country US United States of America
Listing US IGC

About IGC Pharma, Inc.

https://igcpharma.com/

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing treatments for Alzheimer's disease. The company leverages artificial intelligence (AI) in its development process. Its lead candidate, IGC-AD1, is being evaluated in a Phase 2 clinical trial for treating agitation in patients with dementia due to Alzheimer's. The company's pipeline also includes TGR-63, a pre-clinical small molecule designed to inhibit amyloid plaque aggregation. Supporting its therapeutic development is MINT-AD, an AI-powered platform for the early detection of Alzheimer's and to improve the understanding of disease progression.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 87% confidence The document is a U.S. SEC Form 8-K “Current Report” describing the amendment and extension of a Master Loan and Security Agreement (i.e., a financing arrangement). Item 1.01 covers entry into a material definitive financing agreement, which is clearly an update on the company’s financing activities. This matches the “Capital/Financing Update” category (CAP).
2026-06-08 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - IGC Pharma, Inc. (0001326205) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 14, 2026, by IGC Pharma, Inc. It reports the entry into material definitive agreements involving securities purchase agreements and promissory notes with two investors. The document details the terms of these agreements, including principal amounts, interest rates, conversion rights, and use of proceeds. It also references the creation of a direct financial obligation and unregistered sales of equity securities. The content is focused on financing activities and capital structure changes rather than financial results, management changes, or other report types. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (7482 characters) and detailed substantive content support this classification with high confidence.
2026-04-20 English
8-K - IGC Pharma, Inc. (0001326205) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about a strategic national media partnership, which is an 'Other Event' under Item 8.01. The document does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. It is not a certification or a proxy statement. The length is 3921 characters, which is relatively short and consistent with an 8-K filing. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-03-30 English
10-KT - IGC Pharma, Inc. (0001326205) (Filer)
Annual Report Classification · 100% confidence The document is a Form 10-KT filed with the SEC, which is a transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. It covers the transition period from April 1, 2025 to December 31, 2025. The document includes a detailed table of contents with sections such as Business, Risk Factors, Legal Proceedings, Management's Discussion and Analysis, Financial Statements, and Executive Compensation, which are typical components of an annual or transition report. The presence of actual financial statements and substantive financial data confirms it is a comprehensive financial report. Therefore, this filing is best classified as an Annual Report (10-K) type, specifically a transition report variant (10-KT).
2026-03-18 English
4 Filing
Director's Dealing
2026-02-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.